Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (51-60 of 179) with videos related to

Pageof 18
Sort By:
Blood Advances|May 5, 2022
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemiaChong Chyn Chua, Danielle Hammond, Andrew Kent, et al.
Nature Communications|September 14, 2018
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromesBrett M Stevens, Nabilah Khan, Angelo D'Alessandro, et al.
Haematologica|February 18, 2017
Changes in allele frequencies of <i>CSF3R</i> and <i>SETBP1</i> mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinibZohra Nooruddin, Nicholas Miltgen, Qi Wei, et al.
Bone Marrow Transplantation|October 14, 2021
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60Daniel A Pollyea, Amanda Winters, Christine McMahon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2018
Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort ComparisonPrashant Sharma, Daniel A Pollyea, Clayton A Smith, et al.
Leukemia & Lymphoma|September 4, 2024
Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemiaKellen B Gil, Diana Abbott, Maria L Amaya, et al.
Molecular Cytogenetics|July 7, 2022
21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature reviewEmily M Kudalkar, Changlee Pang, Mary M Haag, et al.
Haematologica|September 11, 2025
Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemiaCassandra Duarte, Diana Abbot, Grace Bosma, et al.
Cancer|October 26, 2025
County-level medical debt and treatment initiation among individuals newly diagnosed with cancerJingxuan Zhao, Marcelo Perraillon, Roxanne M Clark, et al.
Experimental Hematology|May 29, 2019
CD123 CAR T cells for the treatment of myelodysplastic syndromeBrett M Stevens, Wei Zhang, Daniel A Pollyea, et al.
Pageof 18

Showing results (51-60 of 179) with videos related to

Sort By:
Pageof 18
Blood Advances|May 5, 2022
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemiaChong Chyn Chua, Danielle Hammond, Andrew Kent, et al.
Nature Communications|September 14, 2018
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromesBrett M Stevens, Nabilah Khan, Angelo D'Alessandro, et al.
Haematologica|February 18, 2017
Changes in allele frequencies of <i>CSF3R</i> and <i>SETBP1</i> mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinibZohra Nooruddin, Nicholas Miltgen, Qi Wei, et al.
Bone Marrow Transplantation|October 14, 2021
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60Daniel A Pollyea, Amanda Winters, Christine McMahon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2018
Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort ComparisonPrashant Sharma, Daniel A Pollyea, Clayton A Smith, et al.
Leukemia & Lymphoma|September 4, 2024
Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemiaKellen B Gil, Diana Abbott, Maria L Amaya, et al.
Molecular Cytogenetics|July 7, 2022
21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature reviewEmily M Kudalkar, Changlee Pang, Mary M Haag, et al.
Haematologica|September 11, 2025
Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemiaCassandra Duarte, Diana Abbot, Grace Bosma, et al.
Cancer|October 26, 2025
County-level medical debt and treatment initiation among individuals newly diagnosed with cancerJingxuan Zhao, Marcelo Perraillon, Roxanne M Clark, et al.
Experimental Hematology|May 29, 2019
CD123 CAR T cells for the treatment of myelodysplastic syndromeBrett M Stevens, Wei Zhang, Daniel A Pollyea, et al.
Pageof 18